Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ARVN
ARVINAS, INC.
NASDAQ
$9.39
▲ UP 0.86% (0.08)

KEY STATISTICS

Market Cap$605.85 M
52w High$14.51
52w Low$6.97
Dividend Yield—
Frequency—
P/E93.90
Volume449.30K
Shares Out.64.52M

COMPANY

LEADERSHIP

Randy Teel
CHIEF EXECUTIVE
Randy Teel

COMPENSATION 2026

Salary$706,236
Stock Awards$2,685,840
Incentive Plan Pay$457,000
All Other Comp.$14,000
Total$6,534,127

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 27, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
246

PRICE TARGET

Target High$20.00
Target Low$10.00
Target Median$12.00
Target Consensus$13.57

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$16.82M
NOV
4
WED

PRICE

$9.39 ▲ UP 0.86% (+$0.08)
$9.22$9.30$9.37$9.459:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM9.39

About Arvinas, Inc.

https://www.arvinas.com ↗

Arvinas, Inc. is a clinical-stage biopharmaceutical company developing PROTAC-based therapies for cancer, with lead candidates targeting prostate and breast cancers, and collaborations with major pharma companies.

INDUSTRY

Biotechnology

A PRODUCT ARVINAS, INC. IS KNOWN FOR

Vepdegestrant (ARV-471)
Vepdegestrant (ARV-471)

Vepdegestrant is an oral PROTAC® targeting estrogen receptors, developed for ER-positive/HER2-negative breast cancer, with an FDA-accepted New Drug Application marking a key milestone for Arvinas.

COMPETITORS

COMPETITOR
AZN COMPARE
CCCC COMPARE
LLY COMPARE
NRIX COMPARE
OLMA COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Collaboration Agreement Revenue— — — $133.7M
License$130M $0 ▼— $62.5M ▲
Milestone Revenue— — — $50M
Reportable Segment— — $15.6M —

ETFS HOLDING THIS STOCK

ETFS HOLDING
131
LISTED HERE
25
RANKED BY POSITION SIZE
VTI
0.00% · 1.9M
XSU.TO
0.02% · 1.5M
XPH
1.38% · 913.4K
FESM
0.06% · 445.5K
SCHA
0.01% · 302.9K
PRFZ
0.07% · 202.5K
DFMC
0.02% · 134.0K
FSCC
0.29% · 130.3K
AVSC
0.03% · 106.5K
CANC
0.38% · 88.6K
EES
0.08% · 62.8K
XRS2.DE
0.02% · 50.6K
GSSC
0.04% · 41.7K
BBC
0.76% · 41.4K
RSSL
0.02% · 28.2K
PILL
0.93% · 23.1K
OASC
0.18% · 18.6K
FSML
0.07% · 10.8K
ESSC
0.12% · 4.8K
BR
BRSM
0.16% · 4.7K
URTY
0.01% · 2.3K
KBFR
0.07% · 955
USFMDN.MX
0.00% · 277
RESM
0.02% · 156
RGSC.L
0.10% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
77.23%
HOLDERS
320
TOP 12 OF 320 · RANKED BY POSITION SIZE
Vanguard Group Inc
8.6M sh · $72.94M
Blackrock, Inc.
7.6M sh · $63.23M
Blackrock Inc.
6.3M sh · $166.61M
Logos Global Management LP
5.6M sh · $47.5M
D. E. Shaw & Co., Inc.
3.7M sh · $43.75M
Pfizer Inc
3.5M sh · $34.92M
Armistice Capital, LLC
2.8M sh · $23.23M
Tcg Crossover Management, LLC
2.7M sh · $31.62M
Two Sigma Investments, LP
2.6M sh · $21.39M
Point72 Asset Management, L.P.
2.3M sh · $27.46M
State Street Corp
2.2M sh · $18.26M
Millennium Management LLC
2.1M sh · $18.16M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity3
Return On Assets3
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score3

INSIDER TRADES

★
DIRECTOR
Norwalk Leslie V
Purchase · 22.7K shares
2026-06-24
★
DIRECTOR
Cunningham Everett
Purchase · 15.5K shares
2026-06-24
★
DIRECTOR
Norwalk Leslie V
Purchase · 15.5K shares
2026-06-24
★
DIRECTOR
Kennedy Edward Moore Jr.
Purchase · 22.7K shares
2026-06-24

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 3
BUY 2
OUTPERFORM 1
EQUAL WEIGHT 1
NEUTRAL 1
SELL 1
9 GRADES IN THE LAST 12 MONTHS
Evercore ISI Group OUTPERFORM Citigroup BUY Wells Fargo EQUAL WEIGHT Wedbush NEUTRAL BTIG BUY Stephens & Co. OVERWEIGHT Barclays OVERWEIGHT Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
ERAS$16.19COMPARE
IOVA$8.79COMPARE
AVBP$30.95COMPARE
MGTX$13.89COMPARE
REPL$15.04COMPARE
GERN$1.57COMPARE
VALN$6.89COMPARE
DNA$6.95COMPARE